IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v550y2017i7674d10.1038_nature24028.html
   My bibliography  Save this article

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Author

Listed:
  • Loren M. Lasko

    (Discovery, Global Pharmaceutical Research and Development)

  • Clarissa G. Jakob

    (Discovery, Global Pharmaceutical Research and Development)

  • Rohinton P. Edalji

    (Discovery, Global Pharmaceutical Research and Development)

  • Wei Qiu

    (Discovery, Global Pharmaceutical Research and Development)

  • Debra Montgomery

    (Discovery, Global Pharmaceutical Research and Development)

  • Enrico L. Digiammarino

    (Discovery, Global Pharmaceutical Research and Development)

  • T. Matt Hansen

    (Discovery, Global Pharmaceutical Research and Development)

  • Roberto M. Risi

    (Discovery, Global Pharmaceutical Research and Development)

  • Robin Frey

    (Discovery, Global Pharmaceutical Research and Development)

  • Vlasios Manaves

    (Discovery, Global Pharmaceutical Research and Development)

  • Bailin Shaw

    (Discovery, Global Pharmaceutical Research and Development)

  • Mikkel Algire

    (Discovery, Global Pharmaceutical Research and Development)

  • Paul Hessler

    (Discovery, Global Pharmaceutical Research and Development)

  • Lloyd T. Lam

    (Discovery, Global Pharmaceutical Research and Development)

  • Tamar Uziel

    (Discovery, Global Pharmaceutical Research and Development)

  • Emily Faivre

    (Discovery, Global Pharmaceutical Research and Development)

  • Debra Ferguson

    (Discovery, Global Pharmaceutical Research and Development)

  • Fritz G. Buchanan

    (Discovery, Global Pharmaceutical Research and Development)

  • Ruth L. Martin

    (Discovery, Global Pharmaceutical Research and Development)

  • Maricel Torrent

    (Discovery, Global Pharmaceutical Research and Development)

  • Gary G. Chiang

    (Discovery, Global Pharmaceutical Research and Development
    eFFECTOR Therapeutics)

  • Kannan Karukurichi

    (Petra Pharma Corporation)

  • J. William Langston

    (Faraday Pharmaceuticals, 1616 Eastlake Ave E.)

  • Brian T. Weinert

    (the Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen)

  • Chunaram Choudhary

    (the Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen)

  • Peter de Vries

    (Cascadian Therapeutics, Inc., 2601 Fourth Avenue)

  • Arthur F. Kluge

    (I-to-D, Inc.)

  • Michael A. Patane

    (Mitobridge, Inc.)

  • John H. Van Drie

    (Van Drie Research, 109 Millpond)

  • Ce Wang

    (China Novartis In stitutes for BioMedical Research)

  • David McElligott

    (Accelerator Corporation)

  • Ed Kesicki

    (Petra Pharma Corporation)

  • Ronen Marmorstein

    (Perelman School of Medicine, University of Pennsylvania)

  • Chaohong Sun

    (Discovery, Global Pharmaceutical Research and Development)

  • Philip A. Cole

    (Johns Hopkins University)

  • Saul H. Rosenberg

    (Discovery, Global Pharmaceutical Research and Development)

  • Michael R. Michaelides

    (Discovery, Global Pharmaceutical Research and Development)

  • Albert Lai

    (Discovery, Global Pharmaceutical Research and Development)

  • Kenneth D. Bromberg

    (Discovery, Global Pharmaceutical Research and Development)

Abstract

A potent and selective catalytic inhibitor of p300/CBP histone acetyltransferases suppresses tumour proliferation across multiple cell lineages, illustrating the therapeutic potential of drug-like small molecules that target histone acetyltransferases.

Suggested Citation

  • Loren M. Lasko & Clarissa G. Jakob & Rohinton P. Edalji & Wei Qiu & Debra Montgomery & Enrico L. Digiammarino & T. Matt Hansen & Roberto M. Risi & Robin Frey & Vlasios Manaves & Bailin Shaw & Mikkel A, 2017. "Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours," Nature, Nature, vol. 550(7674), pages 128-132, October.
    • Handle: RePEc:nat:nature:v:550:y:2017:i:7674:d:10.1038_nature24028
    DOI: 10.1038/nature24028
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature24028
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature24028?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Noha A. M. Shendy & Melissa Bikowitz & Logan H. Sigua & Yang Zhang & Audrey Mercier & Yousef Khashana & Stephanie Nance & Qi Liu & Ian M. Delahunty & Sarah Robinson & Vanshita Goel & Matthew G. Rees &, 2024. "Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300/CBP inhibition," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    2. Cheng Zeng & Jiwei Chen & Emmalee W. Cooke & Arijita Subuddhi & Eliana T. Roodman & Fei Xavier Chen & Kaixiang Cao, 2023. "Demethylase-independent roles of LSD1 in regulating enhancers and cell fate transition," Nature Communications, Nature, vol. 14(1), pages 1-15, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:550:y:2017:i:7674:d:10.1038_nature24028. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.